Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mahasweta Gooptu

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
Blood|March 2, 2023
Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host diseaseAnita G Koshy, Haesook T Kim, Jessica Liegel, et al.
Blood Advances|November 22, 2021
GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trialVincent T Ho, Haesook T Kim, Jennifer Brock, et al.
Blood Advances|January 10, 2024
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AMLJacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Blood Advances|February 7, 2019
PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCLPeter Dreger, Anna Sureda, Kwang Woo Ahn, et al.
Blood Advances|October 6, 2021
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and activeJacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
American Journal of Hematology|October 6, 2025
Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukemia-A Retrospective, Dual-Center StudyOren Pasvolsky, Shai Shimony, Rima M Saliba, et al.
Transplantation and Cellular Therapy|July 6, 2025
Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTRAntonio M Jimenez Jimenez, Stephen R Spellman, Ioannis Politikos, et al.
Biorxiv : the Preprint Server for Biology|November 26, 2025
Early persistence of recipient stem-cells and T-cell dysregulation are associated with relapse after transplant in AML/MDSNurefsan E Sariipek, Ksenia R Safina, Wesley S Lu, et al.
Blood Advances|December 5, 2025
Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AMLJacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Cell Reports Methods|April 29, 2025
Accurate prediction of absolute prokaryotic abundance from DNA concentrationJakob Wirbel, Tessa M Andermann, Erin F Brooks, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Blood|March 2, 2023
Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host diseaseAnita G Koshy, Haesook T Kim, Jessica Liegel, et al.
Blood Advances|November 22, 2021
GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trialVincent T Ho, Haesook T Kim, Jennifer Brock, et al.
Blood Advances|January 10, 2024
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AMLJacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Blood Advances|February 7, 2019
PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCLPeter Dreger, Anna Sureda, Kwang Woo Ahn, et al.
Blood Advances|October 6, 2021
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and activeJacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
American Journal of Hematology|October 6, 2025
Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukemia-A Retrospective, Dual-Center StudyOren Pasvolsky, Shai Shimony, Rima M Saliba, et al.
Transplantation and Cellular Therapy|July 6, 2025
Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTRAntonio M Jimenez Jimenez, Stephen R Spellman, Ioannis Politikos, et al.
Biorxiv : the Preprint Server for Biology|November 26, 2025
Early persistence of recipient stem-cells and T-cell dysregulation are associated with relapse after transplant in AML/MDSNurefsan E Sariipek, Ksenia R Safina, Wesley S Lu, et al.
Blood Advances|December 5, 2025
Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AMLJacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Cell Reports Methods|April 29, 2025
Accurate prediction of absolute prokaryotic abundance from DNA concentrationJakob Wirbel, Tessa M Andermann, Erin F Brooks, et al.
Pageof 7